Compare LARK & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LARK | PROF |
|---|---|---|
| Founded | 1885 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.2M | 270.7M |
| IPO Year | 2001 | 2017 |
| Metric | LARK | PROF |
|---|---|---|
| Price | $24.96 | $5.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 2.7K | ★ 240.2K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.38% | N/A |
| EPS Growth | 1.35 | ★ 25.89 |
| EPS | ★ 2.41 | 1.41 |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | N/A | $115.41 |
| Revenue Next Year | N/A | $60.63 |
| P/E Ratio | $10.31 | ★ $3.94 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $23.43 | $3.90 |
| 52 Week High | $31.04 | $8.95 |
| Indicator | LARK | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 33.67 | 33.47 |
| Support Level | $23.57 | $4.09 |
| Resistance Level | $27.06 | $5.94 |
| Average True Range (ATR) | 0.63 | 0.55 |
| MACD | -0.37 | -0.18 |
| Stochastic Oscillator | 3.83 | 19.16 |
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.